SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1042 8194 "

Sökning: L773:1042 8194

  • Resultat 1-10 av 132
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Abelsson, Johanna, et al. (författare)
  • Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms
  • 2013
  • Ingår i: Leukemia and Lymphoma. - 1042-8194 .- 1029-2403. ; 54:10, s. 2226-2230
  • Tidskriftsartikel (refereegranskat)abstract
    • The quality of life (QoL) at the time of diagnosis of myeloproliferative neoplasm (MPN) has, to date, not been studied. One hundred and seventy-nine patients with MPN: 80 with essential thrombocythemia (ET), 73 with polycythemia vera (PV), 22 with primary myelofibrosis (PMF) and four with MPN undifferentiated, were included in this study. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQC30) and the MPN-Symptom Assessment Form (MPN-SAF) were used to evaluate QoL. Fatigue was the most reported symptom in these patients. Patients with PV reported significantly higher mean scores for inactivity, dizziness, cough, itching, depression and lower total QoL compared to patients with ET. Patients with PV had significantly more headache and itching compared to patients with PMF. When the newly diagnosed patients with MPN were compared with a cohort of patients with MPN with mean disease duration of 7.8 years, the differences were most striking for patients with PMF, with significantly more fatigue, abdominal discomfort, concentration problems, insomnia, fever, weight loss and lower overall QoL developed over time.
  •  
2.
  • Agathangelidis, Andreas, et al. (författare)
  • Stereotyped B-cell receptors in chronic lymphocytic leukemia
  • 2014
  • Ingår i: Leukemia and Lymphoma. - 1042-8194 .- 1029-2403. ; 55:10, s. 2252-2261
  • Forskningsöversikt (övrigt vetenskapligt)abstract
    • Over the last decade, immunogenetic analysis of B-cell receptor immunoglobulins (BcR IGs) has proved to be a particularly fruitful field in chronic lymphocytic leukemia (CLL), not only for understanding disease pathogenesis but also for discriminating clinical subgroups with markedly distinct course and outcome. Of utmost importance was the identification of quasi-identical BcR IGs among unrelated patients with CLL, fittingly coined as "stereotypy," that set the wheels in motion for unraveling the role of antigen(s) in the selection and expansion of the leukemic clones. The categorization of CLL clones into "subsets" according to shared BcR IG structural characteristics provided a compartmentalized view of this otherwise heterogeneous disease, which eventually led to defining strikingly homogeneous groups of patients in terms of: (i) functional properties of the clonal BcR IGs, e. g. BcR reactivity and signaling; (ii) clonal genetic landscape, e. g. genomic aberrations, gene expression/methylation profiles, microRNA signatures; and (iii) clinical course and outcome. The remarkable restriction of the CLL IG gene repertoire, resulting to a great degree from the high impact of BcR IG stereotypy, may also prompt speculations regarding CLL ontogenesis. Overall, the BcR IG molecule justifiably lies at the heart of CLL clinical research, holding the promise of subset-tailored therapies.
  •  
3.
  • Amini, Rose-Marie, et al. (författare)
  • A novel B-cell line (U-2932) established from a patient with a diffuse large B-cell lymphoma following Hodgkin lymphoma
  • 2002
  • Ingår i: Leukemia and Lymphoma. - 1042-8194 .- 1029-2403. ; 43:11, s. 2179-2189
  • Tidskriftsartikel (refereegranskat)abstract
    • Little is known about mechanisms leading to secondary non-Hodgkin lymphomas (NHL) in patients treated for Hodgkin lymphoma (HL). Our aim was to characterise in detail a cell line derived from a diffuse large B-cell lymphoma (DLBCL) that had developed in a patient with relapsing HL. The cell line U-2932 was established from ascites in a patient suffering from DLBCL previously treated for HL with multiple chemotherapy regimens. Characterisation was based on morphology, immunophenotype, Epstein-Barr virus (EBV)-status, IgH gene rearrangement status, tumourigenicity, p53 sequencing, and immunohistochemical expression of p53, BCL-2 and BCL-6. The karyotype was investigated using G-banding, comparative genomic hybridisation (CGH) and spectral karyotype (SKY) analysis. This cell line shows typical morphological features of a DLBCL and grows as colonies in nude mice. It expresses a B-cell phenotype with a somatically hypermutated V(H)4-39 gene and is negative for EBV. The origin of U-2932 was confirmed by demonstrating an identical V(H)4 rearrangement in ascites from the patient. A point mutation of the tumour-suppressor gene p53 was detected in amino acid position 176 and immunohistochemical over-expression of the p53 protein was also demonstrated. U-2932 carries a complex karyotype including high-level amplifications of the chromosomal bands 18q21 and 3q27 and expresses aberrant BCL-2 and BCL-6 immunohistochemically. We were unable to investigate the clonal relationship between the original HL and U-2932. In conclusion, U-2932 is a unique B cell line established from a patient suffering from HL followed by NHL. Overexpression of BCL-2, BCL-6 and p53 may play a role in the tumourigenesis and drug resistance. This cell line may become a useful tool to better understand the mechanisms responsible for development of secondary NHL in patients treated for HL.
  •  
4.
  • Amini, Rose-Marie, et al. (författare)
  • Relapsed Hodgkin's lymphoma : immunostaining patterns in relation to survival
  • 2002
  • Ingår i: Leukemia and Lymphoma. - 1042-8194 .- 1029-2403. ; 43:6, s. 1253-1260
  • Tidskriftsartikel (refereegranskat)abstract
    • Patients with relapsing Hodgkin's lymphoma (HL) have a rather poor prognosis and mechanisms that lead to resistance to therapy are poorly understood. Our aims were to investigate the immunohistochemical staining patterns of Rb (retinoblastoma protein) and the p53 tumour suppressor protein in HL at initial presentation and at relapse in order to elucidate a possible role in disease progression and resistance to therapy. Further to evaluate the presence and prognostic importance of Epstein-Barr virus (EBV) and anaplastic lymphoma kinase (ALK). Eighty-one cases of relapsing HL were reexamined histopathologically and immunostained for the expression of p53, Rb, ALK and CD30. EBV was detected with LMP-1 stainings and in situ hybridisation for EBER. Clinical data were extracted from the Swedish National Health Care Programme for HL. Median follow-up time was six years (range 0-12) from the date of relapse. The majority of cases were positive for p53 and Rb both at presentation and at relapse, though to a different extent. Both an increase and a decrease in the proportion of stained tumour cells were observed. None of our cases was ALK-positive and 44% were EBV-positive. No specific staining pattern was directly correlated to survival. In 12 patients a switch in HL subtype from diagnosis to relapse was observed and the five-year Hodgkin-specific survival (HLS) was statistically significantly inferior, 37 vs 81% (p = 0.002), in those patients. We found a significant relation between the expression of p53 and EBV at diagnosis and relapse, indicating a clonal relationship. We were unable to find any specific staining pattern of p53 or Rb, affecting survival.
  •  
5.
  • Andreasson, Björn, et al. (författare)
  • Plasma erythropoietin concentrations in polycythaemia vera with special reference to myelosuppressive therapy.
  • 2000
  • Ingår i: Leukemia & lymphoma. - 1042-8194. ; 37:1-2, s. 189-95
  • Tidskriftsartikel (refereegranskat)abstract
    • In 80 patients with polycythaemia vera (PV) a total of 108 venous blood samples were obtained and analysed for EDTA-plasma erythropoietin (EPO) concentration. At the time of study 21 of the PV patients were newly diagnosed and had prior to blood sampling neither received phlebotomy treatment nor therapy with myelosuppressive agents; these subjects had a mean plasma EPO concentration of 0.5+/-0.9 IU/L. Thirty-seven patients treated with phlebotomy only had a mean plasma EPO concentration of 2.5+/-2.9 IU/L. The mean plasma EPO concentrations for 26 patients treated with hydroxyurea, 13 patients treated with radiophosphorous and 11 patients given a combination of myelosuppressive agents were 8.9+/-8.0, 10.9+/-12.6 and 7.2+/-7.4 IU/L, respectively. Untreated patients and patients on phlebotomy only had significantly lower values for plasma EPO than patients on therapy with myelosuppressive drugs. This finding persisted also after a correction for differences in haemoglobin levels had been introduced. Thereby, the present results would suggest a difference in the EPO feedback system in untreated and phlebotomised PV patients compared to PV patients treated with myelosuppressive agents.
  •  
6.
  • Andreasson, Björn, et al. (författare)
  • The relation between plasma thrombopoietin and erythropoietin concentrations in polycythaemia vera and essential thrombocythaemia.
  • 2001
  • Ingår i: Leukemia & lymphoma. - 1042-8194. ; 41:5-6, s. 579-84
  • Tidskriftsartikel (refereegranskat)abstract
    • Plasma thrombopoietin (TPO) was measured, by immunoenzymometric assay, in 39 patients with polycythaemia vera (PV), 33 patients with essential thrombocythaemia (ET) and 10 healthy volunteers. The mean TPO concentration was significantly higher in ET patients than in PV patients (p=0.04) and normals (p<0.001). The 6 untreated ET patients had a significantly lower mean TPO concentration compared to the 27 ET patients who were on myelosuppressive regimens (p=0.01). The mean plasma TPO for the 5 PV patients treated with phlebotomy only did not differ significantly from the corresponding mean for the 34 PV patients treated with myelosuppressive agents. Concomitantly, plasma EPO was measured in 25 of the PV patients and in 30 of the ET patients by an immunoradiometric assay with normal reference interval in adults 3.7-16 IU/L. In the 14 PV patients with EPO <3.7 IU/L mean plasma TPO did not differ significantly from the mean for the 11 PV patients with EPO >or=3.7 IU/L; neither of these two groups had plasma TPO concentrations significantly different from the mean for the control subjects. The 7 ET patients with subnormal plasma EPO had significantly lower mean plasma TPO compared to the ET patients with normal and high plasma EPO concentrations (p=0.03 and p=0.02, respectively). Also, the 16 ET patients with normal plasma EPO had significantly lower plasma TPO compared to the 8 patients with high plasma EPO (p=0.04). The mean plasma TPO for each of these three groups of ET patients was significantly higher than the corresponding mean for the controls (p<0.001 for each group). The results of the present study indicate that a relationship between plasma EPO and TPO concentrations may exist and that myelosuppressive treatment affects the TPO concentration in ET but not in PV patients.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 132
Åtkomst
fritt online (9)
Typ av publikation
tidskriftsartikel (111)
konferensbidrag (11)
forskningsöversikt (10)
Typ av innehåll
refereegranskat (97)
övrigt vetenskapligt (34)
populärvet., debatt m.m. (1)
Författare/redaktör
Rosenquist, Richard, (14)
Jerkeman, Mats, (11)
Stamatopoulos, Kosta ... (11)
Enblad, Gunilla, (10)
Sundström, Christer, (9)
Bjorkholm, M, (9)
visa fler...
Berglund, Mattias, (8)
Sundstrom, C, (8)
Kimby, E, (6)
Thunberg, Ulf (6)
Wahlin, Anders, (6)
Hägglund, Hans, (5)
Ghia, Paolo, (5)
Juliusson, Gunnar (5)
Tobin, Gerard (5)
Amini, Rose-Marie, (4)
Juliusson, G (4)
Anagnostopoulos, Ach ... (4)
Linderoth, Johan, (4)
Porwit-MacDonald, A, (4)
Björkholm, Magnus (4)
Rosén, Anders, (4)
Osterborg, A, (3)
Gruber, A. (3)
Hagberg, Hans, (3)
Samuelsson, J, (3)
Johansson, Jan-Erik (3)
Glimelius, Bengt, (3)
Laurell, Anna, (3)
Wadenvik, Hans, 1955 ... (3)
Hagglund, Hans, (3)
Hagglund, H (3)
Remberger, Mats, (3)
Davi, F (3)
Ghia, P (3)
Baliakas, Panagiotis ... (3)
Mansouri, Larry, (3)
Agathangelidis, Andr ... (3)
Scarfo, Lydia, (3)
Sutton, Lesley-Ann, (3)
Vardi, Anna (3)
Hadzidimitriou, Anas ... (3)
Pospisilova, Sarka (3)
Lindén, Ola, (3)
Paul, C, (3)
Ehinger, Mats, (3)
Söderberg, Ola, (3)
Roos, Göran, (3)
Lagercrantz, Svetlan ... (3)
Kutti, Jack, (3)
visa färre...
Lärosäte
Karolinska Institutet (74)
Uppsala universitet (62)
Lunds universitet (28)
Umeå universitet (12)
Linköpings universitet (10)
Örebro universitet (4)
visa fler...
Göteborgs universitet (3)
Malmö universitet (2)
visa färre...
Språk
Engelska (132)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (88)
Naturvetenskap (1)
Teknik (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy